检索结果-南通市图书馆

Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC(CTONG1804):a multicenter open-label phase II study

引用

Signal Transduction and Targeted Therapy 2024年第1期9卷 249-258页

作者： Si-yang Liu Song Dong Xue-Ning yang Ri-Qiang Liao Ben-Yuan jiang Qun Wang Xiao-Song Ben Gui-Bin Qiao Jun-Tao Lin Hong-Hong Yan Li-Xu Yan Qiang Nie Hai-Yan Tu Bin-Chao Wang jin-ji yang Qing Zhou Hong-Rui Li Ke Liu Wendy Wu Si-yang Maggie Liu Wen-Zhao Zhong Yi-Long Wu Guangdong Lung Cancer Institute Guangdong Provincial Key Laboratory of Translational Medicine in Lung CancerGuangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhouChina Department of Thoracic Surgery Zhongshan HospitalFudan UniversityShanghaiChina Department of Thoracic Surgery Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhouChina Department of Pathology Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhouChina Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis FuzhouChina Berry Oncology Corporation FuzhouChina Chinese Thoracic Oncology Group(CTONG) GuangzhouChina Department of Hematology The First Affiliated HospitalJinan UniversityGuangzhouChina

This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive(N)and nivolumab–chemotherapy(N/C)combinations based on PD-L1 *** patients exhibited resectable clinical stage IIA–IIIB(AJCC 8th edition)NSCLC without EGFR/ALK *** received either mono-nivolumab(N)or nivolumab+nabpaclitaxel+carboplatin(N/C)for three cycles based on PD-L1 *** primary endpoint was the major pathological response(MPR).Key secondary endpoints included the pathologic complete response(pCR),objective response rate(ORR),and event-free survival(EFS).Baseline PD-L1 expression and perioperative circulating tumor DNA(ctDNA)status were correlated with pCR and ***-two patients were enrolled,with 46 undergoing *** MPR was 50.0%(26/52),with 25.0%(13/52)achieving pCR,and 16.7%and 66.7%for patients with PD-L1≥50%in N and N/C groups,***(25.0%)patients experienced grade 3 or higher immune-related adverse events during neoadjuvant *** with post-neoadjuvant ctDNA negativity was more likely to have pCR(39.1%)compared with those remained positive(6.7%,odds ratio=6.14,95%CI 0.84-Inf,p=0.077).With a median follow-up of 25.1 months,the 18-month EFS rate was 64.8%(95%CI 51.9–81.0%).For patients with ctDNA–***+,the 18m-EFS rate was 93.8%vs 47.3%(HR,0.15;95%CI 0.04,0.94;p=0.005).Immunochemotherapy may serve as an optimal neoadjuvant treatment even for patients with PD-L1 expression≥50%.ctDNA negativity following neoadjuvant treatment and surgery could help identify superior pathological and survival benefits,which requires further confirmation in a prospective clinical trial(NCT04015778).

关键词： chemotherapy NSCLC treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Insight into early-phase trials for lung cancer in the United States

引用

Chinese Journal of Cancer 2015年第7期34卷 288-294页

作者： jin-ji yang Yi-Long Wu Guangdong Lung Cancer Institute(GLCI) Guangdong General Hospital (GGH)Guangdong Academy of Medical Sciences(GAMS)

Introduction:Few data have been published comparing early-phase trials for lung cancer between China and the United States(US).This study was to investigate the differences of phase 1 trials for lung cancer between these two ***:In 2014,a cross-sectional survey was conducted to compare phase 1 trials for lung cancer between the Guangdong Lung Cancer Institute(GLCI),the University of Wisconsin Carbone Cancer Center(UWCCC),and the University of Texas MD Anderson Cancer Center(MDACC).Results:We found that the GLCI had a lower percentage of phase 1 lung cancer trials than the MDACC in December2014(23.8%[5/21]vs.59.8%[28/47],P = 0.006) and the UWCCC in September 2014(16.7%[3/18]vs.34.8%[8/23],P = 0.345).Descriptive analyses were performed for early-phase trials conducted by the CancerTherapy Evaluation Program at the National Cancer Institute(CTEP/NCI),the MDACC,and the Chinese Thoracic Oncology Group(CTONG).There were 149 ongoing early-phase trials in the Department of Investigational Cancer Therapeutics(Phase 1 program) at the MDACC in October *** contrast,no phase 1 trials had been initiated by the CTONG since its establishment in ***:These data suggest that a significantly higher percentage of phase 1 trials for lung cancer were conducted in the US than in ***-phase oncology trials with robust preclinical data had a higher chance of being approved by the Investigational Drug Branch at the CTEP/*** the importance of early-phase oncology trials in developing innovative cancer medicines,such studies should be highly encouraged and strategically funded in China.

关键词：阶段试验早期肺癌美国 phase Program 临床试验 was

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Role of multi- slice CT urography over ultrasonography in patients with hematuria

引用

东南大学学报（医学版） 2015年第3期34卷 420-424页

作者： DUWADI Ayushma jin ji-yang School of Medicine Southeast University Department of Radiology Zhongda HospitalSoutheast University

Objective:Understanding the role of Multi-slice CT Urography(MSCTU)over Ultrasonography(US)in patients presenting with *** and Methods:Retrospective study enrolled 131 patients presenting with hematuria[microscopic hematuria(n=60)]and macroscopic hematuria(n=71)]who have undergone both MSCTU and US of urinary tract system *** of tests were compared with respective surgical and histopathological analysis of *** cases obtained were bladder carcinoma,ureter carcinoma,renal carcinoma,urinary tract calculi and bladder ***-18thstatistical tool was used for obtaining statistical analysis and final interpretation of ***:The sensitivity and specificity of MSCTU and US for recognition of lesions presenting with macroscopic hematuria were 95.38%,83.33%and 81.54%,66.67%respectively and for those with microscopic hematuria were 96.08%,88.89%and 86.27%,77.8%*** positive and negative likelihood ratios of MSCTU and US in macroscopic category were 5.73,0.055 and 2.46,0.277 respectively while for those in microscopic category were 8.65,0.044 and 3.88,0.176 *** context to the sensitivity of MSCTU and US in patients presenting with macroscopic hematuriathedifferenceswere significant(McNemar's test,P=0.039)suggesting the tests are not similar whereas for those with microscopic hematuria the differences were not significant(Mc Nemar's test,P=2.68)indicatingsimilarity between these ***:Diagnostic efficacy of MSCTU is found to be far superior over US for patients presenting with macroscopic hematuria,thus current practice of using it as a first line modality seems to be ***,for those presenting with microscopic hematuria MSCTU and ultrasonography shows near to similar resultsin accordance to MSCTU,thus US alone seems sufficient to exclude significant urinary tract lesions.

关键词： multi-slice computed urography ultrasonography urinary tract microscopic hematuria macroscopic hematuria

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

An integrated portable bio-monitoring system based on tough hydrogels for comprehensive detection of physiological activities

引用

Nano Research 2024年第1期17卷 321-332页

作者： Congcong yang Chenchen ji Fengjiao Guo Chunjiang jin Hongyu Mi Zhongchang Wang State Key Laboratory of Chemistry and Utilization of Carbon Based Energy Resources School of Chemical Engineering and TechnologyXinjiang UniversityUrumqi 830017China International Iberian Nanotechnology Laboratory(INL) Avenide Mestre Jose VeigaBraga 4715-330Portugal

Advanced soft ion-conducting hydrogels have been developed rapidly in the integrated portable health monitoring equipment due to their higher sensitivity,sensory traits,tunable conductivity,and stretchability for physiological activities and personal healthcare ***,traditional hydrogel conductors are normally susceptible to large deformation and strong mechanical stress,which leads to inferior electro-mechanical stability for real application ***,a strong ionically conductive hydrogel(poly(vinyl alcohol)-boric acid-glycerol/sodium alginate-calcium chloride/electrolyte ions(PBG/SC/EI))was designed by engineering the covalently and ionically crosslinked networks followed by the salting-out effect to further enhance the mechanical strength and ionic conductivity of the *** to the collective effects of the energy-dissipation mechanism and salting-out effect,the designed PBG/SC/EI with excellent structural integrity and robustness exhibits exceptional mechanical properties(elongation at break for 559.1%and tensile strength of 869.4 kPa)and high ionic conductivity(1.618 S·m^(-1)).As such,the PBG/SC/EI strain sensor features high sensitivity(gauge factor=2.29),which can effectively monitor various kinds of human motions(joint motions,facial micro-expression,faint respiration,and voice recognition).Meanwhile,the hydrogel-based Zn||MnO_(2)battery delivers a high capacity of 267.2 mAh·g^(-1)and a maximal energy density of 356.8 Wh·kg^(-1)associated with good cycle performance of 71.8%capacity retention after 8000 ***,an integrated bio-monitoring system with the sensor and Zn||MnO_(2)battery can accurately identify diverse physiological activities in a real-time and non-invasive *** work presents a feasible strategy for designing high-performance conductive hydrogels for highly-reliable integrated bio-monitoring systems with excellent practicability.

关键词： Ionically conductive hydrogel strain sensor Zn-based battery integrated bio-monitoring system human motion monitoring

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

PD-L1表达指导的信迪利单抗与帕博利珠单抗联合或不联合含铂双药化疗治疗未经治晚期非小细胞肺癌患者:一项2期随机对照试验(CTONG1901)

引用

Science Bulletin 2024年第4期69卷 535-543页

作者：刘思阳黄婕邓嘉怡徐崇锐严红虹杨明意黎扬斯柯娥娥郑明英王震林嘉欣甘彬张绪超陈华军汪斌超涂海燕杨衿记钟文昭李扬秋周清吴一龙 Department of Hematology The First Affiliated HospitalJinan UniversityGuangzhou 510632China Guangdong Lung Cancer Institute Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhou 510080China Chinese Thoracic Oncology Group(CTONG) Guangzhou 510055China Institute of Hematology School of MedicineKey Laboratory for Regenerative Medicine of Ministry of EducationJinan UniversityGuangzhou 510632China

No direct comparison has been performed between different programmed cell death-1(PD-1)inhibitors for first-line treatment in patients with advanced non-small cell lung cancer(NSCLC).The feasibility of using PD-L1-expression-guided immunotherapy remains *** this open-label,phase 2 study(NCT04252365),patients with advanced NSCLC without EGFR or ALK alterations were randomized(1:1)to receive sintilimab or pembrolizumab monotherapy(PD-L1 expression≥50%),or sintilimab or pembrolizumab plus platinum-based chemotherapy(PD-L1 expression<50%).The sample size was calculated by optimal two-stage *** primary endpoint was the objective response rate(ORR).The study included 71 patients(sintilimab arms,n=35;pembrolizumab arms,n=36)and met its primary endpoint,with a confirmed ORR of 51.4%(18/35)in the sintilimab *** confirmed ORR(95%confidence interval)was 46.2%(19.2%,74.9%)and 42.9%(17.7%,71.1%)for patients treated with sintilimab and pembrolizumab monotherapy;and 54.5%(32.2%,75.6%)and 45.4%(24.4%,67.8%)for those treated with sintilimab-and pembrolizumab-based combination *** median progression-free survival was6.9 versus 8.1 months for all sintilimab-treated versus all pembrolizumab-treated patients,respectively,in which it was 7.6 versus 11.0 months in monotherapy and 7.4 versus 7.1 months in combination *** median overall survival was 14.9 versus 21.3 months for all sintilimab-treated versus all pembrolizumab-treated patients,respectively,in which it was 14.9 versus 22.6 months in monotherapy and 14.7 versus 17.3 months in combination ***-related adverse events were consistent with safety outcomes of monotherapy and combination therapy in previous phase III ***,the incidence of rash was higher with sintilimab than pembrolizumab *** is the first prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced *** was efficacious and well-tolera

关键词： PD-1 inhibitor Non-small cell lung cancer Pembrolizumab Sintilimab PD-L1 expression

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Adversarial robustness analysis of LiDAR-included models in autonomous driving

引用

High-Confidence Computing 2024年第1期4卷 60-69页

作者： Bo yang Zizhi jin Yushi Cheng Xiaoyu ji Wenyuan Xu College of Electrical Engineering Zhejiang UniversityHangzhou 310027China Hangzhou Zhuoxi Institute of Brain and Intelligence Hangzhou 311100China

In autonomous driving systems,perception is pivotal,relying chiefly on sensors like LiDAR and cameras for environmental ***,celebrated for its detailed depth perception,is being increasingly integrated into autonomous *** this article,we analyze the robustness of four LiDAR-included models against adversarial points under physical *** first introduce an attack technique that,by simply adding a limited number of physically constrained adversarial points above a vehicle,can make the vehicle undetectable by the LiDAR-included *** reveal that adversarial points adversely affect the detection capabilities of both LiDAR-only and LiDAR–camera fusion models,with a tendency for more adversarial points to escalate attack success ***,voxel-based models are more susceptible to deception by these adversarial *** also investigated the impact of the distance and angle of the added adversarial points on the attack success ***,the farther the victim object to be hidden and the closer to the front of the LiDAR,the higher the attack success ***,we have experimentally proven that our generated adversarial points possess good cross-model adversarial transferability and validated the effectiveness of our proposed optimization method through ablation ***,we propose a new plug-and-play,modelagnostic defense method based on the concept of point *** ROC curve of this defense method shows an AUC value of approximately 0.909,demonstrating its effectiveness.

关键词： Autonomous driving LiDAR Adversarial example Defense

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Design and application of copper/lithium composite anodes for advanced lithium metal batteries

引用

Rare Metals 2024年第3期43卷 942-970页

作者： Bin Zhang ji-Ping Ma yang Zhao Tong Li jin-Lin yang Zhan-Ling Zhang Shi-Zhong Wei Guang-Min Zhou School of Materials Science and Engineering Henan University of Science and TechnologyLuoyang 471003China Shenzhen Geim Graphene Center Tsinghua Shenzhen International Graduate SchoolTsinghua UniversityShenzhen 518055China School of Physical and Mathematical Sciences Nanyang Technological UniversitySingapore 637371Singapore Shenzhen Geim Graphene Center Tsinghua-Berkeley Shenzhen InstituteTsinghua Shenzhen International Graduate SchoolTsinghua UniversityShenzhen 518055China

Lithium(Li)is a promising candidate for nextgeneration battery anode due to its high theoretical specific capacity and low reduction ***,safety issues derived from the uncontrolled growth of Li dendrite and huge volume change of Li hinder its practical application.C onstructing dendrite-free composite Li anodes can significantly alleviate the above ***(Cu)-based materials have bee n widely used as substrates of the composite electrodes due to their chemical stability,excellent conductivity,and good mechanical ***/lithium(Cu/Li)composite anodes significantly regulate the local current density and decrease Li nucleation overp otential,realizing the uniform and dendrite-free Li *** this review,Cu/Li composite methods including electrodeposition,melting infusion,and mechanical rolling are systematically summarized and ***,design strategies of Cu-based current collectors for high performance Cu/Li composite anodes are *** challenges and future development for Cu/Li composite anodes are presented and *** hope that this review can provide a comprehensive understanding of Cu/Li composite methods of the latest development of Li metal anode and stimulate more research in the future.

关键词： Lithium metal batteries Cu/Li composite anode Electrodeposition Thermal melting infusion Mechanical rolling

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Na_(3)P interphase reduces Na nucleation energy enabling stable anode-less sodium metal batteries

引用

Journal of Energy Chemistry 2024年第9期96卷 448-455页

作者： Haizhao yang Haifeng Lv En Zhou Xiaohao ji Chunnian Chen Haolei Yu Zhaowei Sun Dawei Zhang Hongchang jin Xianghua Kong Hengxing ji Department of Chemistry and Chemical Engineering Hefei University of TechnologyHefei 230009AnhuiChina Hefei National Research Center for Physical Sciences at the Microscale School of Chemistry and Materials ScienceUniversity of Science and Technology of ChinaHefei 230026AnhuiChina

Sodium metal batteries(SMBs)are rising as viable alternatives to lithium-ion systems due to their superior energy density and sodium's relative ***,SMBs face significant impediments,particularly the exceedingly high negative-to-positive capacity ratios(N/P ratios)which severely encumber energy density and hinder their practical ***,a novel nucleophilic Na_(3)P interphase on aluminum foil has been designed to significantly lower the nucleation energy barrier for sodium atom deposition,resulting in a remarkable reduction of nucleation overpotential and efficient mitigation of dendritic growth at high sodium deposition of 5 mA h cm^(−2).The interphase promotes stable cycling in anode-less SMB configurations with a low N/P ratio of 1.4 and high cathode mass loading of 11.5 mg cm^(−2),and demonstrates a substantial increase in high capacity retention of 92.4%after 500 cycles even under 1 C rate *** innovation signifies a promising leap forward in the development of high-energy-density,anode-less SMBs,offering a potential solution to the longstanding issues of cycle stability and energy efficiency.

关键词： Anode-less Phosphorus anode Nucleation buffer layer Sodium metal Dendrite-free

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial

引用

Chinese Journal of Cancer Research 2012年第2期24卷 97-102页

作者： jin-ji yang Qing Zhou Ri-qiang Liao Yi-sheng Huang Chong-rui Xu Zhen Wang Bin-chao Wang Hua-jun Chen Yi-long Wu Division of Pulmonary Oncology Guangdong Lung Cancer InstituteCancer CenterGuangdong General Hospital&Guangdong Academy of Medical SciencesGuangzhou 510080China

Objective： To evaluate the efficacy and safety of nedaplatin/gemcitabine （NG） and carboplatin/gemcitabine （CG） in the management of untreated advanced non-small cell lung cancer （NSCLC）. Methods： Sixty-two patients with previously untreated advanced NSCLC were recruited between June 2006 and November 2007. Subjects were randomly assigned to the NG arm （n=30） and the CG arm （n=32）. Only patients （24 and 25 in the NG and CG arms, respectively） who completed 〉2 chemotherapy cycles were included in the data analysis. The primary outcome measure was the objective response rate （ORR）. The secondary outcome measures included progression-free survival （PFS）, overall survival （OS） and adverse events. Results： There were no statistically significant differences in the efficacy measures （ORR, P=0.305; median PFS, P=0.298, median OS, P=0.961） or in the major adverse events （grade 3/4 neutropenia, P=0.666; grade 3/4 anemia, P=0.263; grade 3/4 thrombocytopenia, P=0.222） between the two treatment arms. However, there was a trend towards higher ORR （37.5% vs. 24.0%）, longer PFS （6.0 vs. 5.0 months）, and less adverse events in the NG arm. Conclusion： NG regimen seems to be superior over CG regimen for advance NSCLS, but further investigation is needed to validate this superiority.

关键词： Non-small cell lung cancer Chemotherapy Nedaplatin Carboplatin Gemcitabine Squamous cell carcinoma

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Causal temporal graph attention network for fault diagnosis of chemical processes

引用

Chinese Journal of Chemical Engineering 2024年第6期70卷 20-32页

作者： jiaojiao Luo Zhehao jin Heping jin Qian Li Xu ji Yiyang Dai School of Chemical Engineering Sichuan UniversityChengdu 610065China China Three Gorges Corporation Beijing 100038China

Fault detection and diagnosis(FDD)plays a significant role in ensuring the safety and stability of chemical *** the development of artificial intelligence(AI)and big data technologies,data-driven approaches with excellent performance are widely used for FDD in chemical ***,improved predictive accuracy has often been achieved through increased model complexity,which turns models into black-box methods and causes uncertainty regarding their *** this study,a causal temporal graph attention network(CTGAN)is proposed for fault diagnosis of chemical processes.A chemical causal graph is built by causal inference to represent the propagation path of *** attention mechanism and chemical causal graph were combined to help us notice the key variables relating to fault *** in the Tennessee Eastman(TE)process and the green ammonia(GA)process showed that CTGAN achieved high performance and good explainability.

关键词： Chemical processes Safety Fault diagnosis Causal discovery Attention mechanism Explainability

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：